Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma

NCT02482532 is registered in ClinicalTrials.gov with Gary Doolittle as lead sponsor.

NCT NCT02482532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02482532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma
Lead sponsor
Gary Doolittle
Phase
Phase 1
Overall status
Completed
Start date
October 6, 2016
Completion date
September 13, 2021
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma